Alnylam Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yvonne L. Greenstreet
- Full Time Employees
- 2,230
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 675 West Kendall Street Cambridge MA United States of America 02142
- IPO Date
- Jun 1, 2004
- CIK
- 0001178670
- Website
- alnylam.com
- Similar Companies
- Business
- Alnylam Pharmaceuticals, Inc. (ALNY) develops and commercializes RNA interference (RNAi) therapeutics targeting genetically defined diseases; core products include ONPATTRO (patisiran) for hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, AMVUTTRA (vutrisiran) for ATTR amyloidosis with polyneuropathy or cardiomyopathy, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1; the company also advances partnered programs such as Leqvio (inclisiran) for hypercholesterolemia marketed by Novartis. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam operates globally with key facilities in the US, Europe (including France, Italy, Netherlands, Sweden, Switzerland, and the UK), and Japan. The company maintains strategic collaborations with Roche on zilebesiran for hypertension, Regeneron for CNS diseases, Sanofi on fitusiran for hemophilia, and others including Novartis and Agios Pharmaceuticals. Recent developments encompass expansion of AMVUTTRA into ATTR cardiomyopathy with strong launch uptake and upgraded 2025 revenue guidance, initiation of a Phase 1 trial for ALN-4324 targeting GRB14 for type 2 diabetes, and Agios' IND clearance for AG-236 (ALN-TMP) in polycythemia vera; Alnylam joined the Alliance for Genomic Discovery in 2025 to leverage datasets for gene-silencing medicines and extended its partnership with Medison Pharma into LATAM and APAC markets. Pipeline advancements feature nucresiran for ATTR amyloidosis, mivelsiran for Alzheimer's disease and cerebral amyloid angiopathy, and positive Phase 3 data for zilebesiran. These efforts support Alnylam's transition to profitability with 2024 net product revenues exceeding $1.3 billion across rare and cardiometabolic indications.
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts
Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500
Alnylam Bets on AI for Speedy RNAi Drug Discovery and Development
Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion
Alnylam, Inceptive sign up to $2 billion AI drug discovery deal
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Alnylam Issues 2025 Corporate Responsibility Report
Here Are Tuesday’s Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
Alnylam to Webcast Presentations at Upcoming Investor Conferences
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth
Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Year
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2026 Earnings Call Transcript